Company intelligence / Profile preview

BioMarck Pharmaceuticals, Ltd.

Newtown, Pennsylvania, United States6sense.com ↗

Ownership: Private
Development stage: Phase 2

Overview

BIO-11006 demonstrated safety and a 43% reduction in all-cause mortality at 28 days in ARDS Phase 2a trial. In the Phase 2 clinical study for ARDS, rapid improvements in oxygenation were observed in patients receiving BIO-11006 compared to placebo, along with decreases in pro-inflammatory cytokines. At 28 days there were 7 deaths (37%) in the placebo arm and 4 deaths (21%) in the BIO-11006 treatment arm.

Therapeutic areas: OncologyPulmonologyImmunology
Modalities: Peptides
Industry: Biotech

Drug pipeline

3 assets

BIO-11006

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on BioMarck Pharmaceuticals, Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioMarck Pharmaceuticals, Ltd..

Explore the full profile